Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial (vol 76, pg 418, 2017)

Reich K.; Armstrong A. W.; Foley P.; Song M.; Wasfi Y.; Randazzo B.; Li S.; Shen Y-K; Gordon K. B.

首页> 外文期刊>Journal of the American Academy of Dermatology >Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial (vol 76, pg 418, 2017)

【24h】

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial (vol 76, pg 418, 2017)

机译：与随机戒断和后退治疗中度至严重牛皮癣的患者的抗白细胞介素-33单克隆抗体，抗白细胞介素-33单克隆抗体的疗效和安全性：III期，双盲，安慰剂和活性比较的结果 - 受控航行2试验（Vol 76，PG 418,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the American Academy of Dermatology》 |2017年第6期|共1页
作者
Reich K.; Armstrong A. W.; Foley P.; Song M.; Wasfi Y.; Randazzo B.; Li S.; Shen Y-K; Gordon K. B.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献

1. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial (vol 76, pg 418, 2017) [J] . Reich K., Armstrong A. W., Foley P., Journal of the American Academy of Dermatology . 2017,第6期

机译：与随机戒断和后退治疗中度至严重牛皮癣的患者的抗白细胞介素-33单克隆抗体，抗白细胞介素-33单克隆抗体的疗效和安全性：III期，双盲，安慰剂和活性比较的结果 - 受控航行2试验（Vol 76，PG 418,2017）
2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double- blinded, placebo- and active comparator-controlled VOYAGE 1 trial (vol 76, pg 405, 2017) [J] . Blauvelt A., Papp K. A., Griffiths C. E. M., Journal of the American Academy of Dermatology . 2017,第6期

机译：Guselkumab的功效和安全性，抗白细胞介素-33单克隆抗体，与Adalimalab相比，用于连续治疗中度至严重牛皮癣的患者：III期的结果，双盲，安慰剂和活性比较器控制的航程1试验（Vol 76，PG 405,2017）
3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial [J] . Reich Kristian, Armstrong April W., Foley Peter, Journal of the American Academy of Dermatology . 2017,第3期

机译：与Adalensukin-23单克隆抗体的Guselkumab，抗白细胞介素-33单克隆抗体的疗效和安全性与随机戒断和后退治疗中度至严重牛皮癣的患者相比：III期，双盲，安慰剂和活跃的比较结果 - 受控航程2试验
4. Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial [O] . K.A. Papp, A. Blauvelt, A.B. Kimball, -1

机译：用古塞珠单抗或阿达木单抗治疗的患者报告的症状至中重度银屑病：VOYAGE 1随机试验结果
5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis:Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial [O] . Blauvelt, Andrew, Papp, Kim A, Griffiths, Christopher E M, 2017

机译：guerkumab（一种抗白细胞介素-23单克隆抗体）与阿达木单抗相比，用于持续治疗中重度银屑病患者的疗效和安全性：来自III期，双盲，安慰剂和有效比较物控制的VOYaGE 1试验的结果

著录项

相似文献

相关主题

期刊订阅